Page 12 - 2023-08-中国全科医学

2023年3月 第26卷 第8期 http: //www.chinagp.net E-mail: zgqkyx@chinagp.net.cn ·909·

bioconjchem.5b00590. ［25］HOU X Y，LIN H，ZHOU X D，et al. Novel dual ROS-sensitive
［12］KORCHINSKI D J，TAHA M，YANG R Z，et al. Iron oxide as an and CD44 receptor targeting nanomicelles based on oligomeric
MRI contrast agent for cell tracking［J］. Magn Reson Insights， hyaluronic acid for the efficient therapy of atherosclerosis［J］.
2015，8（Suppl 1）：15-29. DOI：10.4137/MRI.S23557. Carbohydr Polym，2020，232：115787. DOI：10.1016/j.
［13］LU K Y，LIN P Y，CHUANG E Y，et al. H 2 O 2 -depleting and carbpol.2019.115787.
O 2 -generating selenium nanoparticles for fluorescence imaging ［26］KIM H，KUMAR S，KANG D W，et al. Affinity-driven design
and photodynamic treatment of proinflammatory-activated of cargo-switching nanoparticles to leverage a cholesterol-rich
macrophages［J］. ACS Appl Mater Interfaces，2017，9（6）： microenvironment for atherosclerosis therapy［J］. ACS Nano，
5158-5172. DOI：10.1021/acsami.6b15515. 2020，14（6）：6519-6531. DOI：10.1021/acsnano.9b08216.
［14］KOSUGE H，SHERLOCK S P，KITAGAWA T，et al. Near ［27］BOADA C，ZINGER A，TSAO C，et al. Rapamycin-
infrared imaging and photothermal ablation of vascular inflammation loaded biom im etic nanoparticles revers e vas cular
using single-walled carbon nanotubes［J］. J Am Heart Assoc， inflammation［J］. Circ Res，2020，126（1）：25-37. DOI：
2012，1（6）：e002568. DOI：10.1161/JAHA.112.002568. 10.1161/CIRCRESAHA.119.315185.
［15］CHHOUR P，NAHA P C，O'NEILL S M，et al. Labeling ［28］BELDMAN T J，MALINOVA T S，DESCLOS E，et al.
monocytes with gold nanoparticles to track their recruitment in Nanoparticle-aided characterization of arterial endothelial
atherosclerosis with computed tomography［J］. Biomaterials， architecture during atherosclerosis progression and metabolic
2016，87：93-103. DOI：10.1016/j.biomaterials.2016.02.009. therapy［J］. ACS Nano，2019，13（12）：13759-13774.
［16］QIN J B，PENG Z Y，LI B，et al. Gold nanorods as a theranostic DOI：10.1021/acsnano.8b08875.
platform for in vitro and in vivo imaging and photothermal therapy of ［29］KIM M，SAHU A，HWANG Y，et al. Targeted delivery of anti-
inflammatory macrophages［J］. Nanoscale，2015，7（33）： inflammatory cytokine by nanocarrier reduces atherosclerosis in
-/-
13991-14001. DOI：10.1039/c5nr02521d. Apo E mice［J］. Biomaterials，2020，226：119550. DOI：
［17］SUK J S，XU Q G，KIM N，et al. PEGylation as a strategy for 10.1016/j.biomaterials.2019.119550.
improving nanoparticle-based drug and gene delivery［J］. Adv ［30］WANG Y Q，LI L L，ZHAO W B，et al. Targeted therapy of
Drug Deliv Rev，2016，99（Pt A）：28-51. DOI：10.1016/j. atherosclerosis by a broad-spectrum reactive oxygen species
addr.2015.09.012. scavenging nanoparticle with intrinsic anti-inflammatory
［18］LIANG X Y，LI H Y，ZHANG A A，et al. Red blood cell activity［J］. ACS Nano，2018，12（9）：8943-8960. DOI：
biomimetic nanoparticle with anti-inflammatory，anti-oxidative 10.1021/acsnano.8b02037.
and hypolipidemia effect ameliorated atherosclerosis therapy［J］. ［31］CHMIELOWSKI R A，ABDELHAMID D S，FAIG J J，et al.
Nanomed-Nanotechnol Biol Med，2022，41：102519. DOI： Athero-inflammatory nanotherapeutics：ferulic acid-based poly
10.1016/j.nano.2022.102519. （anhydride-ester） nanoparticles attenuate foam cell formation
［19］MEHTA S，BONGCARON V，NGUYEN T K，et al. An by regulating macrophage lipogenesis and reactive oxygen species
ultrasound-responsive theranostic cyclodextrin-loaded nanoparticle generation［J］. Acta Biomater，2017，57：85-94. DOI：
for multimodal imaging and therapy for atherosclerosis［J］. Small， 10.1016/j.actbio.2017.05.029.
2022，18（31）：e2200967. DOI：10.1002/smll.202200967. ［32］SONG Y N，HUANG Z Y，LIU X，et al. Platelet membrane-
［20］FANG F，NI Y H，YU H C，et al. Inflammatory endothelium- coated nanoparticle-mediated targeting delivery of Rapamycin
targeted and cathepsin responsive nanoparticles are effective against blocks atherosclerotic plaque development and stabilizes plaque
-/-
atherosclerosis［J］. Theranostics，2022，12（9）：4200-4220. in apolipoprotein E-deficient （ApoE ） mice［J］. Nanomed-
DOI：10.7150/thno.70896. Nanotechnol Biol Med，2019，15（1）：13-24. DOI：10.1016/j.
［21］GAO C，LIU C H，CHEN Q，et al. Cyclodextrin-mediated nano.2018.08.002.
conjugation of macrophage and liposomes for treatment of ［33］FAVARI E，THOMAS M J，SORCI-THOMAS M G. High-
atherosclerosis［J］. J Control Release，2022，349：2-15. DOI： density lipoprotein functionality as a new pharmacological target
10.1016/j.jconrel.2022.06.053. on cardiovascular disease：unifying mechanism that explains
［22］PHAM L M，KIM E C，OU W Q，et al. Targeting and clearance high-density lipoprotein protection toward the progression of
of senescent foamy macrophages and senescent endothelial cells atherosclerosis［J］. J Cardiovasc Pharmacol，2018，71（6）：
by antibody-functionalized mesoporous silica nanoparticles for 325-331. DOI：10.1097/FJC.0000000000000573.
alleviating aorta atherosclerosis［J］. Biomaterials，2021，269： ［34］MANSUKHANI N A，PETERS E B，SO M M，et al. Peptide
120677. DOI：10.1016/j.biomaterials.2021.120677. amphiphile supramolecular nanostructures as a targeted therapy
［23］WANG Y，ZHANG K，LI T H，et al. Macrophage membrane for atherosclerosis［J］. Macromol Biosci，2019，19（6）：
functionalized biomimetic nanoparticles for targeted anti- e1900066. DOI：10.1002/mabi.201900066.
atherosclerosis applications［J］. Theranostics，2021，11（1）： ［35］CHIN D D，POON C，TRAC N，et al. Collagenase-cleavable
164-180. DOI：10.7150/thno.47841. peptide amphiphile micelles as a novel theranostic strategy in
［24］DHANASEKARA C S，ZHANG J，NIE S F，et al. Nanoparticles atherosclerosis［J］. Adv Ther （Weinh），2020，3（3）：
target intimal macrophages in atherosclerotic lesions［J］. 1900196. DOI：10.1002/adtp.201900196.
Nanomed-Nanotechnol Biol Med，2021，32：102346. DOI： ［36］AHERN R J，HANRAHAN J P，TOBIN J M，et al. Comparison of
10.1016/j.nano.2020.102346. fenofibrate-mesoporous silica drug-loading processes for enhanced